Cytotoxicity of bcr-abl-specific CD4+T-lymphocyte clones
| Clone . | Target . | Peptide added . | % Specific lysis4-150 . | ||
|---|---|---|---|---|---|
| 10:1 . | 5:1 . | 2.5:1 . | |||
| MY-1 | Autologous DCs | None | 3.3 ± 0.2 | 2.1 ± 0.2 | 0.4 ± 0.1 |
| b3a2 | 74.1 ± 4.8 | 63.9 ± 5.8 | 58.3 ± 3.2 | ||
| b2a2 | 4.0 ± 0.5 | 3.0 ± 0.4 | 0.2 ± 0.2 | ||
| CML DCs | None | 0.4 ± 0.2 | 2.6 ± 0.1 | 0.3 ± 0.2 | |
| b3a2 | 69.4 ± 6.9 | 53.9 ± 3.5 | 49.2 ± 4.1 | ||
| b2a2 | 1.5 ± 0.3 | 2.2 ± 0.5 | 0.3 ± 0.1 | ||
| TO-1 | Autologous DCs | None | 0.4 ± 0 | 0 ± 0.1 | 0 ± 0.5 |
| b3a2 | 63.6 ± 3.0 | 55.2 ± 6.3 | 47.3 ± 4.6 | ||
| b2a2 | 0.3 ± 0 | 0 ± 0 | 0.5 ± 0.5 | ||
| CML DCs | None | 0.4 ± 0.2 | 0 ± 0 | 0 ± 0.3 | |
| b3a2 | 52.9 ± 4.5 | 45.3 ± 6.1 | 36.0 ± 2.6 | ||
| b2a2 | 0.6 ± 0.2 | 0.2 ± 0.6 | 0 ± 0 | ||
| Clone . | Target . | Peptide added . | % Specific lysis4-150 . | ||
|---|---|---|---|---|---|
| 10:1 . | 5:1 . | 2.5:1 . | |||
| MY-1 | Autologous DCs | None | 3.3 ± 0.2 | 2.1 ± 0.2 | 0.4 ± 0.1 |
| b3a2 | 74.1 ± 4.8 | 63.9 ± 5.8 | 58.3 ± 3.2 | ||
| b2a2 | 4.0 ± 0.5 | 3.0 ± 0.4 | 0.2 ± 0.2 | ||
| CML DCs | None | 0.4 ± 0.2 | 2.6 ± 0.1 | 0.3 ± 0.2 | |
| b3a2 | 69.4 ± 6.9 | 53.9 ± 3.5 | 49.2 ± 4.1 | ||
| b2a2 | 1.5 ± 0.3 | 2.2 ± 0.5 | 0.3 ± 0.1 | ||
| TO-1 | Autologous DCs | None | 0.4 ± 0 | 0 ± 0.1 | 0 ± 0.5 |
| b3a2 | 63.6 ± 3.0 | 55.2 ± 6.3 | 47.3 ± 4.6 | ||
| b2a2 | 0.3 ± 0 | 0 ± 0 | 0.5 ± 0.5 | ||
| CML DCs | None | 0.4 ± 0.2 | 0 ± 0 | 0 ± 0.3 | |
| b3a2 | 52.9 ± 4.5 | 45.3 ± 6.1 | 36.0 ± 2.6 | ||
| b2a2 | 0.6 ± 0.2 | 0.2 ± 0.6 | 0 ± 0 | ||
The results shown represent the means ± SDs of triplicate experiments.
Cytotoxicity of MY-1 and TO-1 against autologous mature DCs and HLA-DRB1*0901-bearing mature DCs derived from the patients with b3a2 type CML was determined by 4-hour 51Cr release assays at effector:target ratios of 10:1, 5:1, and 2.5:1.